Micron-size drug particles:: Common and novel micronization techniques

被引:262
作者
Rasenack, N [1 ]
Müller, BW [1 ]
机构
[1] Univ Kiel, Dept Pharmaceut & Biopharmaceut, D-24118 Kiel, Germany
关键词
micron-size drug; milling techniques; micronization; surface characterization; controlled crystallization; supercritical fluid; in situ micronization; particle engineering;
D O I
10.1081/PDT-120027417
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug powders containing micron-size drug particles are used in several pharmaceutical dosage forms. Many drugs, especially newly developed substances, are poorly water soluble, which limits their oral bioavailability. The dissolution rate can be enhanced by using micronized drugs. Small drug particles are also required in administration forms, which require the drug in micron-size size due to geometric reasons in the organ to be targeted (e.g., drugs for pulmonary use). The common technique for the preparation of micron-size drugs is the mechanical comminution (e.g., by crushing, grinding, and milling) of previously formed larger particles. In spite of the widespread use of this technique, the milling process does not represent the ideal way for the production of small particles because drug substance properties and surface properties are altered in a mainly uncontrolled manner. Thus, techniques that prepare the drug directly in the required particle size are of interest. Because physicochemical drug powder properties are decisive for the manufacturing of a dosage form and for therapeutic success, the characterization of the particle surface and powder properties plays an important role. This article summarizes common and novel techniques for the production of a drug in small particle size. The properties of the resulting products that are obtained by different techniques are characterized and compared.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 99 条
[41]   EFFECT OF RESS DYNAMICS ON POLYMER MORPHOLOGY [J].
LELE, AK ;
SHINE, AD .
INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH, 1994, 33 (06) :1476-1485
[42]  
List M., 1988, GB Patent, Patent No. 2200048
[43]  
Liversidge G.G., 1992, USP Pat, Patent No. [5145684, US5145684]
[44]  
LIVERSIDGE GG, 2000, Patent No. 6068858
[45]  
LIVERSIDGE GG, 1997, Patent No. 5628981
[46]   PROPERTIES AND DISSOLUTION OF DRUGS MICRONIZED BY CRYSTALLIZATION FROM SUPERCRITICAL GASES [J].
LOTH, H ;
HEMGESBERG, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 32 (2-3) :265-267
[47]   The impact of low levels of amorphous material (<5%) on the blending characteristics of a direct compression formulation [J].
Mackin, L ;
Sartnurak, S ;
Thomas, I ;
Moore, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 231 (02) :213-226
[48]   RAPID EXPANSION OF SUPERCRITICAL FLUID SOLUTIONS - SOLUTE FORMATION OF POWDERS, THIN-FILMS, AND FIBERS [J].
MATSON, DW ;
FULTON, JL ;
PETERSEN, RC ;
SMITH, RD .
INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH, 1987, 26 (11) :2298-2306
[49]   MECHANICALLY ACTIVATED MOO3 .1. PARTICLE-SIZE, CRYSTALLINITY, AND MORPHOLOGY [J].
MESTL, G ;
HERZOG, B ;
SCHLOGL, R ;
KNOZINGER, H .
LANGMUIR, 1995, 11 (08) :3027-3034
[50]   MECHANICALLY ACTIVATED MOO3 .2. CHARACTERIZATION OF DEFECT STRUCTURES [J].
MESTL, G ;
VERBRUGGEN, NFD ;
KNOZINGER, H .
LANGMUIR, 1995, 11 (08) :3035-3041